# CORVUS PHARMACEUTICALS INC (CRVS)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/CRVS/

- Reporting holders: 5
- Reported value: $416.0K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [AVITY INVESTMENT MANAGEMENT INC.](https://holderbook.com/funds/926834-avity-investment-management-inc/) | $400.9K | 34,800 | 0.0% | 13 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $13.2K | 1,149 | 0.0% | 5 |
| [EASTERN BANK](https://holderbook.com/funds/1126395-eastern-bank/) | $1.1K | 92 | 0.0% | 2 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $449 | 39 | 0.0% | 4 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $323 | 28 | 0.0% | 3 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 5 | $416.0K |
| Q2 2026 | 175 | $1.2B |
| Q1 2026 | 166 | $1.1B |
| Q4 2025 | 127 | $369.8M |
| Q3 2025 | 107 | $311.1M |
| Q2 2025 | 97 | $169.3M |
| Q1 2025 | 93 | $122.2M |
| Q4 2024 | 91 | $227.5M |
| Q3 2024 | 65 | $165.4M |
| Q2 2024 | 48 | $50.4M |
| Q1 2024 | 48 | $33.1M |
| Q4 2023 | 47 | $34.5M |